Burning Rock Biotech (NASDAQ:BNR) Downgraded to “Hold” Rating by Wall Street Zen

Burning Rock Biotech (NASDAQ:BNR) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Burning Rock Biotech currently has an average rating of “Sell”.

Burning Rock Biotech Stock Performance

Shares of NASDAQ BNR opened at $8.59 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.79 and a current ratio of 3.05. The company has a market cap of $90.37 million, a P/E ratio of -10.48 and a beta of 1.32. The firm’s fifty day moving average is $15.44 and its two-hundred day moving average is $21.12. Burning Rock Biotech has a 52-week low of $3.06 and a 52-week high of $41.72.

Burning Rock Biotech (NASDAQ:BNR) last announced its quarterly earnings results on Tuesday, June 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.29) by $2.09. The company had revenue of $15.66 million for the quarter, compared to the consensus estimate of $19.21 million. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%.

Insider Activity

In other Burning Rock Biotech news, Director Yusheng Han bought 314,870 shares of the firm’s stock in a transaction dated Tuesday, March 31st. The shares were purchased at an average cost of $17.36 per share, for a total transaction of $5,466,143.20. Following the transaction, the director owned 17,672,676 shares of the company’s stock, valued at $306,797,655.36. This represents a 1.81% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 30.30% of the company’s stock.

Institutional Trading of Burning Rock Biotech

Several hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC raised its position in shares of Burning Rock Biotech by 13.8% during the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after buying an additional 4,290 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Burning Rock Biotech during the 4th quarter valued at about $220,000. Crcm LP raised its position in shares of Burning Rock Biotech by 121.8% during the 4th quarter. Crcm LP now owns 491,426 shares of the company’s stock valued at $9,902,000 after buying an additional 269,851 shares in the last quarter. Prospera Financial Services Inc raised its position in shares of Burning Rock Biotech by 26.0% during the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after buying an additional 6,430 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in shares of Burning Rock Biotech during the 3rd quarter valued at about $26,000. 30.03% of the stock is currently owned by hedge funds and other institutional investors.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.